RION Appoints Alisa Lask as Chief Commercial Officer
- Two active FDA registrations
ROCHESTER, Minn.--(BUSINESS WIRE)-- RION, a biotechnology company headquartered in Rochester, Minnesota pioneering new innovations in exosomes for therapeutic and aesthetic indications, today announced the appointment of Alisa Lask as Chief Commercial Officer.
“Alisa brings an exemplary track record gained through both global and U.S. leadership roles at Galderma, Allergan, Zimmer-Biomet, and Eli Lilly and Company, showing significant capability to spearhead commercial strategies to create world-class aesthetic and therapeutic product franchises,” said Dr. Atta Behfar, Founder of RION. “She has proven skills in leading large commercial organizations, launching brands, driving revenue and profitability while fostering a high-performing organization. We are pleased to have an experienced industry leader who can help build a strong commercial infrastructure commensurate with the breakthrough potential of our proprietary Regenerative Exosomes.”
“I am honored for the opportunity to join RION, especially given the company’s breakthrough technology in which I see clear potential,” said Lask. “Regenerative medicine is the future and will garner meaningful adoption with advancements in technology. I look forward to introducing the first truly novel off-the-shelf regenerative medicine since the category was created.”
“The Board and I have great confidence Alisa has the strategic vision, extensive industry knowledge, and operational experience needed to drive growth and lead RION to continued success,” continued Dr. Behfar. “She has a proven track record of accomplishments, industry relationships, and unparalleled experience that bring great benefit to our company’s aesthetics and therapeutic portfolio. Alisa also brings a personal style fully aligned with our values and culture, making her a natural fit for the team.”
Alisa holds a Master of Business Administration from the University of Michigan and a bachelor’s degree in marketing from Miami University, Oxford, Ohio. She currently serves on the Board of Directors for Collpant (Nasdaq: CLGN) and Nephros (Nasdaq: NEPH).
RION is a clinical-stage regenerative medicine company focused on developing innovative exosome therapeutics that are clinically impactful and broadly accessible. RION has developed Purified Exosome Product™ (PEP™), an innovative biologic platform that harnesses the therapeutic power of exosomes for regenerative medicine. RION was established in 2017 through the Mayo Clinic Employee Entrepreneurial Program and is headquartered in Rochester, Minnesota. For more information, visit www.riontx.com.